无症状与有症状COVID-19对急性缺血性卒中血运重建结局的影响
这项国际多中心回顾性队列研究纳入2020至2021年接受静脉溶栓和血管内治疗的连续急性缺血性卒中患者,比较COVID阴性对照、无症状COVID-19(AS-COVID)与有症状COVID-19(S-COVID)的血运重建安全性和结局。结果显示AS-COVID和S-COVID均与更高的症状性颅内出血和更差临床结局相关,有症状感染者影响更明显且再通结局更差。
要点
- AS-COVID与S-COVID均与症状性颅内出血风险升高相关(aOR分别为1.43和1.63)。
- 仅S-COVID与24小时和3个月死亡率显著升高相关(aOR分别为2.97和2.64)。
- S-COVID与更低成功再通率(74.9% vs 85.6%)和更低首过再通率(20.3% vs 28.3%)相关。
核心结论
- 在接受血运重建治疗的急性缺血性卒中患者中,AS-COVID和S-COVID均影响颅内出血风险和更差的临床结局。
- 有症状感染者这种效应的幅度更明显,且再通结局更不利。
- 这些发现强调SARS-CoV-2感染对血运重建后急性缺血性卒中预后的影响不依赖于症状状态。
研究设计与样本
- 国际多中心回顾性队列研究,纳入2020至2021年接受静脉溶栓和血管内治疗的连续急性缺血性卒中并检测SARS-CoV-2的患者。
- 共纳入105个中心的15124例患者,中位年龄71岁,49%为男性,39%仅接受静脉溶栓,61%接受血管内治疗±静脉溶栓。
- 采用多变量回归比较COVID阴性对照、AS-COVID和S-COVID。
主要发现
- 849例(5.6%)患有COVID-19,其中395例(46%)无症状,454例(54%)有症状。
- 症状性颅内出血率:COVID阴性对照5%,AS-COVID 7.6%(aOR 1.43,95% CI 1.03-1.99),S-COVID 9.4%(aOR 1.63,95% CI 1.14-2.32)。
- 24小时死亡率:COVID阴性对照1.3%,S-COVID 4.8%(aOR 2.97,95% CI 1.76-5.03);3个月死亡率:COVID阴性对照19.5%,S-COVID 40%(aOR 2.64,95% CI 2.06-3.37)。
- 3个月残疾更差的改良Rankin量表评分位移aOR:AS-COVID 1.25(95% CI 1.03-1.51),S-COVID 2.10(95% CI 1.75-2.53)。
- S-COVID较对照有更低成功再通率(74.9% vs 85.6%,P<0.001)、更低首过再通率(20.3% vs 28.3%,P=0.005)和更高通过次数。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The association of COVID-19 with higher bleeding risk and worse outcomes in acute ischemic stroke (AIS) undergoing revascularization may be related to the presence of infection symptoms. We aimed to assess the safety and outcomes of revascularization treatments in patients with AIS with asymptomatic COVID-19 (AS-COVID) or symptomatic COVID-19 (S-COVID). METHODS: We conducted an international multicenter retrospective cohort study of consecutive AIS tested for SARS-CoV-2, receiving intravenous thrombolysis and endovascular treatment between 2020 and 2021. We compared COVID-negative controls, AS-COVID, and S-COVID using multivariable regression. We assessed symptomatic intracranial hemorrhage (symptomatic intracerebral hemorrhage), mortality, and 3-month disability (modified Rankin Scale score). RESULTS: Among 15 124 patients from 105 centers (median age, 71 years; 49% men; 39% treated with intravenous thrombolysis only; and 61% with endovascular treatment±intravenous thrombolysis), 849 (5.6%) had COVID-19, of whom 395 (46%) were asymptomatic and 454 (54%) symptomatic. Compared with controls, both patients with AS-COVID and S-COVID had higher symptomatic intracerebral hemorrhage rates (COVID-controls, 5%; AS-COVID, 7.6%; S-COVID, 9.4%; adjusted odds ratio [aOR], 1.43 [95% CI, 1.03-1.99]; aOR, 1.63 [95% CI, 1.14-2.32], respectively). Only in patients with symptomatic infections, we observed a significant increase in mortality at 24 hours (COVID-controls, 1.3%; S-COVID, 4.8%; aOR, 2.97 [95% CI, 1.76-5.03]) and 3 months (COVID-controls, 19.5%; S-COVID, 40%; aOR, 2.64 [95% CI, 2.06-3.37]). Patients with COVID-19 had worse 3-month disability regardless of disease symptoms although disability was affected to a greater extent in symptomatic patients (aOR for worse modified Rankin Scale score shift: AS-COVID, 1.25 [95% CI, 1.03-1.51]; S-COVID, 2.10 [95% CI, 1.75-2.53]). S-COVID had lower successful recanalization (74.9% versus 85.6%; P<0.001), first pass recanalization (20.3% versus 28.3%; P=0.005), and a higher number of passes. CONCLUSIONS: In AIS undergoing revascularization treatments, both AS-COVID and S-COVID influence the risk of intracranial bleeding and worse clinical outcomes. The magnitude of this effect is more pronounced in symptomatic infections, which also present less favorable recanalization outcomes. These findings emphasize the impact of SARS-CoV-2 infection on the prognosis of revascularized AIS independent of symptom status. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04895462.
引用
- Strambo D, Marto JP, Ntaios G, et al. Effect of Asymptomatic and Symptomatic COVID-19 on Acute Ischemic Stroke Revascularization Outcomes. Stroke. 2023. PMID: 38134260. doi:10.1161/STROKEAHA.123.043899
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。